Sara Mangsbo, PhDProfessor at Uppsala UniversitySpeaker
Profile
Sara Mangsbo, Professor Uppsala University and CSO/founder of Immuneed AB. Sara defended her thesis in 2010 around local immune modulation of bladder cancer and continued with a postdoctoral period in Professor Melief and Professor Ossendorp’s laboratory at LUMC in the Netherlands. The project involved how to use long peptide vaccines in an immune complex formulation to enhance antigen delivery into dendritic cells.
She has continued the work in Sweden in collaboration with Associate professor Drijfhout and taken the project into a preclinical drug development project. She is also active in the antibody therapy field with antibodies targeting CD40 and checkpoint blockers. She has been part in the preclinical development project of ADC1013 that is now in clinical trial, an antibody that was licensed to JnJ in 2015.
Agenda Sessions
Enhancing Neoantigen Peptide Delivery with Affinity-Based CD40 Targeting Antibody Conjugates
, 11:20View Session